VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Hassan on Immunotherapy in Malignant Pleural Mesothelioma

Raffit Hassan, MD
Published: Monday, Jan 09, 2017



Raffit Hassan, MD, head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute Center for Cancer Research discusses immunotherapy in malignant pleural mesothelioma.

There are 2 major forms of immunotherapy used to treat mesothelioma, both of which are in advanced clinical testing. Amatuximab is used in the frontline setting and targets the anti-mesothelin tumor. The other is anetumab ravtansine, which is an antibody-drug conjugate in the second-line setting.

The other class of immunotherapy drugs that might potentially benefit patients with mesothelioma are checkpoint inhibitors. Fifteen percent to 20% of patients with mesothelioma have seen long-lasting shrinkage in their tumors, although it is not yet determined who will benefit. No drug has been approved since 2004, making the outcome of the clinical trials for mesothelin-targeted agents and immune checkpoint antibodies vital to the future treatment of mesothelioma.
 


Raffit Hassan, MD, head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute Center for Cancer Research discusses immunotherapy in malignant pleural mesothelioma.

There are 2 major forms of immunotherapy used to treat mesothelioma, both of which are in advanced clinical testing. Amatuximab is used in the frontline setting and targets the anti-mesothelin tumor. The other is anetumab ravtansine, which is an antibody-drug conjugate in the second-line setting.

The other class of immunotherapy drugs that might potentially benefit patients with mesothelioma are checkpoint inhibitors. Fifteen percent to 20% of patients with mesothelioma have seen long-lasting shrinkage in their tumors, although it is not yet determined who will benefit. No drug has been approved since 2004, making the outcome of the clinical trials for mesothelin-targeted agents and immune checkpoint antibodies vital to the future treatment of mesothelioma.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x